Pharmacokinetics of 14 C-ciclesonide after oral and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Dry powder inhaled ribavirin in healthy volunteers: safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017
Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Pharmacokinetics of tiotropium administered by Respimat in adolescent asthma patients Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Population pharmacokinetics of nebulized arformoterol in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009